Reference Source

Egis Pharmaceuticals PLC · 66-66 · HUNGARY

For Egis Pharmaceuticals PLC · 66-66 · HUNGARY, import alert is 66-66; import alert name is "APIs That Appear To Be Misbranded Under 502(f)(1) Because They Do Not Meet The Requirements For The Labeling Exemptions In 21 CFR 201.122"; country is HUNGARY; product code is 61 U - - 05 Tamoxifen Citrate (Anti-Estrogen); date published is 09/30/2009; address is Kereszturi Ut 30-38 , Budapest, Budapest HUNGARY, verified against its source on 2026-09-16.

Firm
Egis Pharmaceuticals PLC verified
Import alert
66-66
Import alert name
"APIs That Appear To Be Misbranded Under 502(f)(1) Because They Do Not Meet The Requirements For The Labeling Exemptions In 21 CFR 201.122"
Country
HUNGARY verified
Address
Kereszturi Ut 30-38 , Budapest, Budapest HUNGARY verified
Date published
09/30/2009 verified
Product code
61 U - - 05 Tamoxifen Citrate (Anti-Estrogen) verified
FDA notes
11/2/2000 verified
Sourceaccessdata.fda.gov
Verified
Review by
DatasetFDA import alert red lists: firms subject to detention without physical examination

What the source says

Egis Pharmaceuticals PLC Date Published : 09/30/2009 Kereszturi Ut 30-38 , Budapest, Budapest HUNGARY 61 U - - 05 Tamoxifen Citrate (Anti-Estrogen) Date Published: 09/30/2009 Notes: 11/2/2000

accessdata.fda.gov, retrieved 2026-09-15

Source

Last verified against source: . Due for re-check by . This page as Markdown · OKF bundle · full dataset as JSON.

This one changes, and we watch it.FDA import alert red lists: firms subject to detention without physical examination is re-read on a schedule and every change is dated. Subscribe: Atom feed · JSON · what has changed so far.